SG11201811100RA - Treatment of retinal vascular disease using progenitor cells - Google Patents
Treatment of retinal vascular disease using progenitor cellsInfo
- Publication number
- SG11201811100RA SG11201811100RA SG11201811100RA SG11201811100RA SG11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- johnson
- rule
- pennsylvania
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662358389P | 2016-07-05 | 2016-07-05 | |
| PCT/US2017/039660 WO2018009385A1 (en) | 2016-07-05 | 2017-06-28 | Treatment of retinal vascular disease using progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811100RA true SG11201811100RA (en) | 2019-01-30 |
Family
ID=59363222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811100RA SG11201811100RA (en) | 2016-07-05 | 2017-06-28 | Treatment of retinal vascular disease using progenitor cells |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180015129A1 (ja) |
| EP (1) | EP3481405A1 (ja) |
| JP (1) | JP2019524688A (ja) |
| KR (1) | KR20190026758A (ja) |
| CN (1) | CN109414460A (ja) |
| AR (1) | AR108972A1 (ja) |
| AU (1) | AU2017291707A1 (ja) |
| BR (1) | BR112019000059A2 (ja) |
| CA (1) | CA3029997A1 (ja) |
| MA (1) | MA45623A (ja) |
| MX (1) | MX2019000050A (ja) |
| PH (1) | PH12018502704A1 (ja) |
| RU (1) | RU2019102933A (ja) |
| SG (1) | SG11201811100RA (ja) |
| TW (1) | TW201811344A (ja) |
| WO (1) | WO2018009385A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114712393B (zh) * | 2020-12-18 | 2024-01-19 | 中国人民解放军海军军医大学第三附属医院 | Hnf-1α基因修饰的间充质干细胞在防治肝癌中的用途 |
| CN115014908A (zh) * | 2022-05-23 | 2022-09-06 | 江西中医药大学 | 染色剂、心脏切片制备方法及微血管灌注染色评价方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| ATE357468T1 (de) | 1999-04-16 | 2007-04-15 | Univ Wm Marsh Rice | Bioabbaubare mit polypropylenfumaratdiacrylat- makromonomeren vernetzte polypropylenfumarat- netzwerke |
| US6355699B1 (en) | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
| US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US9969980B2 (en) | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| WO2005001080A2 (en) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| PL1979050T3 (pl) * | 2005-12-28 | 2017-09-29 | DePuy Synthes Products, Inc. | Leczenie chorób naczyń obwodowych z zastosowaniem komórek pochodzenia poporodowego |
-
2017
- 2017-06-28 US US15/636,140 patent/US20180015129A1/en not_active Abandoned
- 2017-06-28 BR BR112019000059A patent/BR112019000059A2/pt not_active IP Right Cessation
- 2017-06-28 CA CA3029997A patent/CA3029997A1/en not_active Abandoned
- 2017-06-28 WO PCT/US2017/039660 patent/WO2018009385A1/en unknown
- 2017-06-28 EP EP17740522.2A patent/EP3481405A1/en not_active Withdrawn
- 2017-06-28 AU AU2017291707A patent/AU2017291707A1/en not_active Abandoned
- 2017-06-28 MX MX2019000050A patent/MX2019000050A/es unknown
- 2017-06-28 JP JP2018568884A patent/JP2019524688A/ja active Pending
- 2017-06-28 MA MA045623A patent/MA45623A/fr unknown
- 2017-06-28 RU RU2019102933A patent/RU2019102933A/ru not_active Application Discontinuation
- 2017-06-28 SG SG11201811100RA patent/SG11201811100RA/en unknown
- 2017-06-28 KR KR1020197001133A patent/KR20190026758A/ko unknown
- 2017-06-28 CN CN201780041905.5A patent/CN109414460A/zh active Pending
- 2017-07-03 TW TW106122179A patent/TW201811344A/zh unknown
- 2017-07-05 AR ARP170101862A patent/AR108972A1/es unknown
-
2018
- 2018-12-20 PH PH12018502704A patent/PH12018502704A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12018502704A1 (en) | 2019-11-11 |
| CA3029997A1 (en) | 2018-01-11 |
| WO2018009385A1 (en) | 2018-01-11 |
| MX2019000050A (es) | 2019-05-02 |
| RU2019102933A (ru) | 2020-08-05 |
| MA45623A (fr) | 2019-05-15 |
| JP2019524688A (ja) | 2019-09-05 |
| EP3481405A1 (en) | 2019-05-15 |
| TW201811344A (zh) | 2018-04-01 |
| AU2017291707A1 (en) | 2019-01-03 |
| BR112019000059A2 (pt) | 2019-10-01 |
| AR108972A1 (es) | 2018-10-17 |
| US20180015129A1 (en) | 2018-01-18 |
| KR20190026758A (ko) | 2019-03-13 |
| CN109414460A (zh) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201900361RA (en) | Methods of treating prostate cancer |